1、1 0 D ec em b er 2 0 2 4Q125Financial ResultsA p r i l 2 4,2 0 2 5Forward-Looking StatementsStatements included in this press release that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.Gilead cautions readers th

2、at forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially.These risks and uncertainties include those relating to:Gileads ability to achieve its full year 2025 financial guidance,including as a result of the uncertainty of the a

3、mount and timing of Veklury revenues,the impact of the Inflation Reduction Act,changes in U.S.regulatory or legislative policies,and changes in U.S.trade policies,including tariffs;Gileads ability to make progress on any of its long-term ambitions or priorities laid out in its corporate strategy;Gil

4、eads ability to accelerate or sustain revenues for its virology,oncology and other programs;Gileads ability to realize the potential benefits of acquisitions,collaborations or licensing arrangements,including the acquisitions of CymaBay,and Immunomedics,and the arrangement with LEO Pharma;patent pro

5、tection and estimated loss of exclusivity for our products and product candidates;Gileads ability to initiate,progress or complete clinical trials within currently anticipated timeframes or at all,the possibility of unfavorable results from ongoing and additional clinical trials,including those invo

6、lving Biktarvy,Trodelvy,lenacapavir,teropavimab and zinlirvimab,and the risk that safety and efficacy data from clinical trials may not warrant further development of Gileads product candidates or the product candidates of Gileads strategic partners;Gileads ability to submit new drug applications fo